Navigation Links
Bradmer provides Phase III Neuradiab trial update and guidance
Date:10/15/2007

TSX: BMR

TORONTO, Oct. 15 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that it held a pre-Phase III meeting with the U.S. Food and Drug Administration (FDA) at which the FDA concurred with Bradmer's proposed design of the Phase III trial for its lead drug, Neuradiab, a treatment for newly diagnosed glioblastoma multiforme (GBM), the most common form of brain cancer.

At the recent meeting, the FDA responded favorably to the Company's presentation of its full clinical plan which included the trial protocol, standard operating procedures, statistical plan, and related documents.

"We initiated this discussion with the FDA to establish clarity around the appropriate clinical structure of a multicenter trial that would be suitable for the potential registration of Neuradiab," commented Alan M. Ezrin, Ph.D., President and Chief Executive Officer of Bradmer. "We are delighted with the FDA's response to the presentation of our clinical plans, which were developed in conjunction with the FDA, with our collaborators at Duke University and with thought leaders in neurooncology and neurosurgery."

Bradmer and the FDA discussed and agreed to the study trial design which includes an enhanced statistical power calculation of 90% and an added interim efficacy analysis. The agreed design, which will allow for the enrollment of approximately 380 patients in each of the experimental and control arms, has the possibility to actually shorten the study trial duration and to improve the statistical probability of success. Bradmer anticipates a 24-month enrollment period and an interim efficacy analysis on overall survival at approximately month 39 post-trial initiation, or at 470 mortality events. Should an additional efficacy analysis be required, it would occur at 626 events.

Prior to the initiatio
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Protein provides antioxidant protection to Neurons
2. Acupuncture provides relief
3. Micro-camera provides new breast imaging technique
4. Hormone therapy provides no heart benefit
5. MicroRNA provides new insight into birth defects
6. Drug Spironolactone Provides Renal And Cardioprotection In Diabetic Patients
7. Neurobiology Provides Answers To Block Memory-Related Drug Cravings
8. Cholesterol provides immunity against infection by certain parasites
9. John Hopkins CGHH program provides Global Health education
10. London Hospital Provides Specialized Care For Pregnant Women
11. Hope Lodges provides free stay to cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Thompson HealthDay Reporter THURSDAY, ... wars that break out regularly between outspoken celebrities or loudmouth ... own relationship, a new study suggests. High amounts of ... if the couple is in a long-term relationship, according to ... In turn, that friction can lead to cheating and breakups, ...
(Date:7/10/2014)... responders felt better prepared to respond to an active ... a new study in the journal Prehospital and ... specifically examine the EMS provider comfort level with respect ... yet been neutralized or working with law enforcement personnel ... High School shooting, the Virginia Tech campus shooting, the ...
(Date:7/10/2014)... amount of alcoholic beverages consumed, even for light-to-moderate ... risk of coronary heart disease, lower body mass ... new multi-center study published in The BMJ ... Medicine at the University of Pennsylvania. The latest ... that consuming light-to-moderate amounts of alcohol (0.6-0.8 fluid ...
(Date:7/10/2014)... The U.S. Department of Health and Human Services ... (UH) Case Medical Center Seidman Cancer Center totaling $4.7 ... improving care for patients with complex cancer. , ... unique model developed at UH to enhance care for ... demonstrated need for high health care utilization. ...
(Date:7/10/2014)... imaging far outweigh the risks when children receive The ... Radiation Dose. However, overuse and misuse of imaging change ... collaborative effort to ensure a national protocol is put ... Journal of Patient Safety , calls for the American ... Commission, and the Centers for Medicare & Medicaid Services ...
Breaking Medicine News(10 mins):Health News:Are You Tweeting Your Marriage Away? 2Health News:Are You Tweeting Your Marriage Away? 3Health News:Active shooter training increases comfort level of emergency responders 2Health News:New study shows drinking alcohol provides no heart health benefit 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2
... Analysis of a drug regimen approved by the F.D.A. ... (bevacizumab added to the standard chemotherapy regimen carboplatin and paclitaxel) ... received this regimen did not have improved survival compared to ... alone, according to a study in the April 18 issue ...
... The Prospective Surveillance Model, an innovative new model of breast ... American Cancer Society,s journal, Cancer released on April ... by women with breast cancer and offers hope for an ... through rehabilitation and exercise. APTA members Nicole ...
... (Toronto) People with an opioid addiction had the highest risk ... drugs, according to a new study by the Centre for ... on opioids, the risk of death was 5.71 times higher ... gender and race. Those with methamphetamine use disorders were next ...
... plays an integral role in physical health dates back to ... referred to as the founder of medicine, wrote "natural ... University of Missouri team has tapped into the science and ... award-winning program. Called "Taking Care of You: Body-Mind-Spirit," ...
... undergoing chemoradiation therapy (CRT) for head and neck cancer, ... short-term improvement in swallowing function; however, there were no ... and controls at nine or 12 months following treatment, ... Archives of Otolaryngology Head & Neck Surgery ...
... MONDAY, April 16 (HealthDay News) -- Tattoos and body piercings ... in western societies, but a new study in France found ... than their peers. In the study, researchers asked ... they left bars and other drinking establishments. The readings showed ...
Cached Medicine News:Health News:Study examines drug regimen for the treatment of non-small cell lung cancer among older patients 2Health News:Study examines drug regimen for the treatment of non-small cell lung cancer among older patients 3Health News:Model for breast cancer rehab featured in supplement to ACS journal, Cancer 2Health News:Opioids associated with highest risk of death 2Health News:MU receives national award for using mind-body approach to improve health 2Health News:Swallowing exercises linked with short-term improvement among patients with head and neck cancer 2Health News:Tattoos, Piercings Tied to Heavier Drinking in French Study 2
(Date:7/10/2014)... R.I. , July 10, 2014 CVS Caremark ... board of directors has approved a quarterly dividend of $0.275 ... dividend is payable on August 1, 2014, to holders of ... CVS Caremark is dedicated to helping people ... pharmacy company in the United States . ...
(Date:1/15/2014)... Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... used on patients in order to treat dental impairments, ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), a ... with abnormal auto-immune responses and inflammation, has selected the ... large scale GMP clinical and pre-commercial supplies of A-623, ... of autoimmune diseases. "Establishing a rapid and ...
... Reportlinker.com announces that a new market research report ... 2010 Pharmaceuticals Research Review ... slowdown has accentuated the fault lines already dividing ... large pharma companies, coupled with the patent expiration ...
Cached Medicine Technology:Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Anthera's Investigational Novel Peptibody Agent 2Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Anthera's Investigational Novel Peptibody Agent 3Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Anthera's Investigational Novel Peptibody Agent 4Reportlinker Adds 2010 Pharmaceuticals Research Review 2Reportlinker Adds 2010 Pharmaceuticals Research Review 3Reportlinker Adds 2010 Pharmaceuticals Research Review 4Reportlinker Adds 2010 Pharmaceuticals Research Review 5Reportlinker Adds 2010 Pharmaceuticals Research Review 6Reportlinker Adds 2010 Pharmaceuticals Research Review 7Reportlinker Adds 2010 Pharmaceuticals Research Review 8Reportlinker Adds 2010 Pharmaceuticals Research Review 9Reportlinker Adds 2010 Pharmaceuticals Research Review 10Reportlinker Adds 2010 Pharmaceuticals Research Review 11Reportlinker Adds 2010 Pharmaceuticals Research Review 12Reportlinker Adds 2010 Pharmaceuticals Research Review 13Reportlinker Adds 2010 Pharmaceuticals Research Review 14
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: